next-generation antibody Market

The global next-generation antibody market is expected to reach US$ 12,050.13 million by 2028 from US$ 5,428.41 million in 2021; it is estimated to grow at a CAGR of 11.9% from 2021 to 2028.

The market for next-generation antibody therapeutics is growing due to rising incidence of cancer and increased demand. However, challenges in manufacturing and obtaining approvals hinder its growth.

Next-generation antibodies are more specific and powerful than traditional monoclonal antibodies. These antibodies require advanced engineering to ensure stability, targeted delivery, and minimal off-target effects.

The next-generation antibody market is divided into therapeutic area, technology, and geography. By therapeutic area, the market is split into oncology and autoimmune/inflammatory, with the oncology segment having the larger share in 2021 and projected to have a higher growth rate. By technology, the next-generation antibody market is segmented into antibody-drug conjugates, bispecific antibodies, Fc engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products. The antibody-drug conjugates segment is expected to dominate the market, while the bispecific antibodies segment is projected to have the highest growth rate due to increased usage in treating various diseases globally. The antibody-drug conjugates (ADCs) segment is anticipated to hold the largest share of the next-generation antibody market for several reasons. ADCs have emerged as a promising class of next-generation antibodies due to their ability to selectively deliver potent cytotoxic drugs to target cells. This targeted approach minimizes the damage to healthy cells, thereby reducing the risk of adverse effects and improving treatment outcomes. Secondly, ADCs have shown remarkable efficacy in the treatment of various cancers, including breast cancer, lymphoma, and leukemia. This has resulted in a surge in demand for ADCs and has propelled their adoption in the healthcare industry. Thirdly, several key players in the pharmaceutical industry have invested heavily in the development of ADCs, leading to a significant expansion in the product pipeline. This increased focus on research and development is expected to further fuel the growth of the ADCs segment in the next-generation antibody industry. Overall, the potential advantages of ADCs over traditional chemotherapy and the increasing investment in their development make them a promising segment in the next-generation antibody market, which is why they are expected to hold the largest share in the market.

The report on the next-generation antibody market was created with primary and secondary sources such as Globocan statistics, World Health Organization (WHO), International Agency for Research on Cancer (IARC), and Organization for Economic Co-operation and Development (OECD).